SLC6A1-Related Epilepsy

SLC6A1-Related Epilepsy

Overview

SLC6A1-related epilepsy is a genetic epilepsy syndrome caused by heterozygous pathogenic variants in the [SLC6A1](/entities/slc6a1) gene, which encodes GAT-1 (GABA transporter 1), the principal transporter responsible for reuptake of GABA from the synaptic cleft. Loss of GAT-1 function leads to impaired GABA clearance, desensitization of GABA-A receptors, and network hyperexcitability. The most common phenotype is myoclonic-atonic epilepsy (MAE), also known as Doose syndrome, though the spectrum ranges from childhood absence epilepsy to severe developmental encephalopathy[@slc6a1_2015][@slc6a1_2018].

Genetics and Molecular Basis

SLC6A1 Gene

[SLC6A1](/entities/slc6a1) is located on chromosome 3p25.3 and encodes GAT-1, a sodium- and chloride-dependent GABA transporter. GAT-1 is expressed in both neurons and astrocytes and is responsible for:

• Reuptake of synaptic GABA into presynaptic terminals (primary mechanism)
• Astrocytic uptake of GABA for recycling or metabolism
• Regulation of extracellular GABA concentrations
• Prevention of GABA spillover to adjacent synapses

Pathophysiology

GAT-1 is the dominant GABA transporter in the brain. When GAT-1 function is reduced:

GABA persists longer in the synaptic cleft

Initial excessive GABA receptor activation leads to receptor desensitization

Compensatory downregulation of GABA-A receptor expression may occur

Net effect: reduced effective inhibition → network hyperexcitability

Variant Types

...

SLC6A1-Related Epilepsy

Overview

SLC6A1-related epilepsy is a genetic epilepsy syndrome caused by heterozygous pathogenic variants in the [SLC6A1](/entities/slc6a1) gene, which encodes GAT-1 (GABA transporter 1), the principal transporter responsible for reuptake of GABA from the synaptic cleft. Loss of GAT-1 function leads to impaired GABA clearance, desensitization of GABA-A receptors, and network hyperexcitability. The most common phenotype is myoclonic-atonic epilepsy (MAE), also known as Doose syndrome, though the spectrum ranges from childhood absence epilepsy to severe developmental encephalopathy[@slc6a1_2015][@slc6a1_2018].

Genetics and Molecular Basis

SLC6A1 Gene

[SLC6A1](/entities/slc6a1) is located on chromosome 3p25.3 and encodes GAT-1, a sodium- and chloride-dependent GABA transporter. GAT-1 is expressed in both neurons and astrocytes and is responsible for:

• Reuptake of synaptic GABA into presynaptic terminals (primary mechanism)
• Astrocytic uptake of GABA for recycling or metabolism
• Regulation of extracellular GABA concentrations
• Prevention of GABA spillover to adjacent synapses

Pathophysiology

GAT-1 is the dominant GABA transporter in the brain. When GAT-1 function is reduced:

GABA persists longer in the synaptic cleft

Initial excessive GABA receptor activation leads to receptor desensitization

Compensatory downregulation of GABA-A receptor expression may occur

Net effect: reduced effective inhibition → network hyperexcitability

Variant Types

| Variant Type | Frequency | Typical Impact |
|-------------|-----------|----------------|
| Missense | ~50% | Reduced transporter function; variable severity |
| Nonsense | ~25% | Premature truncation; absent protein |
| Frameshift | ~10% | Loss-of-function; typically severe |
| Splice site | ~10% | Aberrant mRNA; variable |
| Copy number | ~5% | Deletions/duplications |

Epidemiology

| Metric | Value |
|--------|-------|
| Prevalence | ~1:10,000-20,000 for MAE; SLC6A1 accounts for ~1-2% of genetic epilepsies |
| Inheritance | Autosomal dominant (de novo in ~90% of cases) |
| Sex ratio | Equal males and females |
| Seizure onset | 1-5 years (MAE); 4-10 years (CAE) |

Clinical Presentation

Myoclonic-Atonic Epilepsy (MAE / Doose Syndrome)

The most common presentation of [SLC6A1](/entities/slc6a1) variants:

Seizure types:

• Myoclonic seizures: Sudden, brief jerks of limbs or face; often multiple per day
• Atonic seizures: Sudden loss of muscle tone ("drop attacks"); most disabling feature
• Absence seizures: Typical 3 Hz spike-wave; may be brief
• Tonic-clonic seizures: Generalized convulsive seizures
• Myoclonic-atonic: Combined seizures

Course:

• Onset typically 1-5 years
• Initially may present with febrile seizures or generalized tonic-clonic
• Myoclonic-atonic pattern emerges over months
• Variable response to ASMs
• Cognitive outcome varies: ~40-50% have normal IQ, ~50-60% have ID

Childhood Absence Epilepsy (CAE) Phenotype

A subset of [SLC6A1](/entities/slc6a1) patients present with pure absence seizures resembling classical CAE:

• Onset 4-10 years
• Typical 3 Hz spike-wave on EEG
• Less severe cognitive outcome
• May remit or persist into adulthood

Genotype-Phenotype Correlations

• Missense variants in transmembrane domains: More likely to cause MAE
• Missense variants in extracellular loops: May cause milder CAE phenotype
• Truncating variants: More likely associated with developmental delay, ID

Diagnosis

Clinical Diagnosis

Features suggesting [SLC6A1](/entities/slc6a1)-related epilepsy:

Onset 1-5 years with myoclonic/atonic seizures

Multiple seizure types (myoclonic, atonic, absence, tonic-clonic)

Generalized EEG patterns (4-6 Hz spike-wave)

Variable cognitive outcome

Family history (autosomal dominant)

Genetic Confirmation

• Epilepsy gene panel: Tests SLC6A1 along with other MAE genes (SCN1A, CHD2, etc.)
• Whole exome sequencing: Identifies SLC6A1 and other causes
• SLC6A1-targeted analysis: Confirm known family variant

EEG and Neuroimaging

• EEG: Generalized spike-wave (3-6 Hz), photosensitivity common; background normal to mildly abnormal
• MRI: Usually normal; no specific structural findings

Treatment

Anti-Seizure Medications

SLC6A1 epilepsy is variable in ASM response. Valproic acid is typically first-line:

| Drug | Evidence | Notes |
|------|----------|-------|
| Valproic acid | Moderate | Broad-spectrum; first-line for MAE |
| Ethosuximide | Moderate | Effective for absence component; limited for myoclonic/atonic |
| Clobazam | Low-moderate | Adjunct; tachyphylaxis common |
| Stiripentol | Low-moderate | May help as add-on |
| Levetiracetam | Low | Often ineffective |
| Tiagabine | AVOID | GAT-1 inhibitor — would worsen condition by further reducing GABA reuptake |

Non-Pharmacologic Therapies

• Ketogenic diet: May help some patients; mechanism may compensate for GABAergic dysfunction
• Vagus nerve stimulation (VNS): Option for refractory cases

Gene Therapy Approach

[SLC6A1](/entities/slc6a1) is an excellent gene therapy target:

• Clear monogenic loss-of-function mechanism
• Well-characterized pathophysiology
• Small gene size (~1.8 kb coding) fits easily in AAV
• Preclinical data in Slc6a1 knockout mice support approach

Takeda/SB-001 Program

SB-001 (formerly TX-004, developed by Takeda/Shinobi/Recode) is an AAV-based gene therapy delivering functional SLC6A1 (GAT-1) to neurons:

• Delivers wild-type SLC6A1 coding sequence
• Uses neuronal-specific promoter (synapsin)
• Targets neurons to restore GABA reuptake
• Delivered via ICV or intrathecal administration

Preclinical data in Slc6a1 knockout mice showed:

• Partial restoration of GABA uptake activity
• Reduced seizure susceptibility
• Improved behavioral outcomes

See [AAV gene therapy hub](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy) for more on the SLC6A1 program.

Prognosis

| Outcome | Details |
|---------|---------|
| Seizure outcome | Variable; 20-40% achieve seizure freedom with treatment |
| Cognitive outcome | 40-50% normal IQ; 50-60% mild-moderate ID |
| Long-term | Many improve with age; some maintain seizures into adulthood |
| SUDEP risk | Present but lower than Dravet or Lennox-Gastaut |

Research and Open Questions

GAT-1 compensation — are GAT-2/GAT-3 upregulated in response to GAT-1 loss?

Therapeutic threshold — what percentage of wild-type GAT-1 levels is sufficient?

Critical period — when must SLC6A1 function be restored?

ASM selection — which patients respond best to which medications?

Biomarkers — what indicates successful GAT-1 restoration (EEG? GABA levels?)?

References

[@slc6a1_2015] [SLC6A1 myoclonic-atonic epilepsy: clinical and genetic characterization](https://pubmed.ncbi.nlm.nih.gov/25741990/)

[@slc6a1_2018] [GAT-1 dysfunction and epilepsy: insights from SLC6A1 variants](https://pubmed.ncbi.nlm.nih.gov/30198980/)